STAREE: Fewer Cardiovascular Events After 70, but No Proven Gain in Disability-Free Survival

The STAREE trial offers one of the largest comparisons of cardiovascular prevention in older people with no known cardiovascular disease. It enrolled 9,971 community-dwelling adults aged 70 or over who had no history of cardiovascular disease, diabetes or dementia. Participants were randomly assigned atorvastatin or placebo and followed for a median of 5.9 years. The results, published in The New England Journal of Medicine, show why longevity studies need to distinguish disease prevention from preserving independence.

Two outcomes, two answers

A first cardiovascular event of the type defined by the trial occurred in 297 participants assigned atorvastatin and 412 assigned placebo. The hazard ratio was 0.70: in the time-to-event analysis, the estimated relative hazard was 30% lower. That does not mean thirty in every hundred people avoided an event. The difference depends on the starting risk, the length of follow-up and how the outcome was defined.

The other measure combined death, dementia and persistent physical disability. It was recorded in 637 participants in the treatment group and 676 in the placebo group; the difference was not statistically significant. The conclusion is specific: the trial found a cardiovascular benefit but did not demonstrate that treatment extended time free of the problems included in the second outcome. Neither finding cancels out the other.

What this adds to longevity research

Disability-free survival depends on more than cardiovascular health. An intervention can improve an important clinical outcome without producing a clear difference in a measure that also captures other causes. STAREE’s contribution was to ask both questions in the same population rather than assume that answering one would settle the other.

The distinction also matters for future trials. A combined outcome can capture several important changes, but researchers still need to explain which events occurred and how often. The cardiovascular result and the measure of independence belong alongside one another, each with its own uncertainty.

The study provides evidence on primary prevention in a selected population. It does not determine what is right for every patient or what to do when a statin is already indicated for a diagnosed condition. The next time a healthy-ageing trial makes headlines, ask what the researchers measured, in whom and over what period. Here, those three questions change the meaning of the headline.

Sources: The STAREE trial in The New England Journal of Medicine. Illustrative photograph: Pexels.